Irvine, CA—Algae Health Sciences, a division of BGG, announced in a press release the publication of two double-blind, placebo-controlled human clinical trials using AstaZine on brain health.
In the first study, healthy subjects aged 26 to 63 took AstaZine for 8 weeks. The study found significant improvements in feelings of depression, mental fatigue, and overall mood state, and the researchers noted trends toward improvement in other mental health parameters including tension, anger, and confusion.
Related: Acetyl-L-Carnitine and Cognitive Health
12 Ways Astaxanthin Can Help Athletes and Active People: The Athlete’s Dozen
64% of Supplement Users Take A Supplement Daily, According to TTC Survey
The second study was performed on healthy adults who were experiencing mild forgetfulness. After 12 weeks taking AstaZine, the treatment group showed a statistically significant improvement versus placebo on two tests for cognitive function and memory. Both verbal and composite memory significantly improved as tested by Cognitrax, and subjective assessment of symptoms were judged by the AstaZine group as having significantly improved.
Yanmei Li, Ph.D., Chief Scientific Officer of BGG, said in the release: “We’re extremely pleased to have two additional successful clinical trials for AstaZine under our belt. Our goal is to maintain a leadership role in the botanical sector through innovation and continuing scientific discoveries.”
Talbott, S., Hantla, D., Capelli, B., Ding, L., Li, Y., Artaria, C. “Astaxanthin Supplementation Reduces Depression and Fatigue in Healthy Subjects.” EC Nutrition 14.3 (2019): 239-246.
Sekikawa, T., Kizawa, Y., Li, Y., Takara., T. “Cognitive Function Improvement with Astaxanthin Intake: A Randomized, Double-Blind, Placebo-Controlled Study.” Pharmacometrics 97 (1/2) 1-13 (2019).